---
title: 'Outcome after treatment with axitinib in children, young adults, and adults
  with renal cell carcinoma: a narrative review'
date: '2024-09-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39326645/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240927184334&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Renal cell carcinoma (RCC) is a very rare type of renal cancer in children
  and young adults. When metastasized or recurrent, no standards of care are available,
  and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for
  treatment of RCC in adults, but its effects in children and young adults with RCC
  remains unclear. Due to the histological and biological differences between children
  and adults, it is difficult to extrapolate knowledge on treatments from the adult
  to ...
disable_comments: true
---
Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to ...